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The plasma membrane of eukaryotic cells contains several types of lipids displaying high
biochemical variability in both their apolar moiety (e.g., the acyl chain of glycerolipids)
and their polar head (e.g., the sugar structure of glycosphingolipids). Among these lipids,
cholesterol is unique because its biochemical variability is almost exclusively restricted
to the oxidation of its polar −OH group. Although generally considered the most rigid
membrane lipid, cholesterol can adopt a broad range of conformations due to the flexibility
of its isooctyl chain linked to the polycyclic sterane backbone. Moreover, cholesterol is
an asymmetric molecule displaying a planar α face and a rough β face. Overall, these
structural features open up a number of possible interactions between cholesterol and
membrane lipids and proteins, consistent with the prominent regulatory functions that
this unique lipid exerts on membrane components. The aim of this review is to describe
how cholesterol interacts with membrane lipids and proteins at the molecular/atomic
scale, with special emphasis on transmembrane domains of proteins containing either
the consensus cholesterol-binding motifs CRAC and CARC or a tilted peptide. Despite
their broad structural diversity, all these domains bind cholesterol through common
molecular mechanisms, leading to the identification of a subset of amino acid residues that
are overrepresented in both linear and three-dimensional membrane cholesterol-binding
sites.
Keywords: cholesterol, CH-Pi, lipid-protein interaction, lipid raft, neurotransmitter, receptor structure, alpha-
synuclein, Alzheimer
INTRODUCTION
Transmembrane domains of proteins cross the lipid bilayer of
biological membranes to ensure the insertion of a subset of
amino acid residues within the membrane. These proteins are
usually referred to as integral membrane proteins. Deciphering
the molecular mechanisms allowing the interaction of these pro-
teins with membrane lipids has been and still is the subject of
intense research efforts at the crossroad of several scientific areas
including biochemistry, biophysics, cell biology, and bioinformat-
ics. Basically, a transmembrane domain is an α-helical segment of
ca. 20–25 apolar amino acid residues flanked at each end by more
polar residues allowing them to “float” at the lipid-water interface
region of the membrane, thereby stabilizing the helix within the
lipid bilayer (Lee, 2003). These “interfacial” amino acid residues
have to manage the transition between an apolar and a polar
environment. For this reason, Lys, Arg, Tyr, and Trp residues are
most commonly found at these flanking positions. Lys and Arg
have a long apolar side chain buried in the apolar section of the
membrane, and a positively charged basic group that “breathes”
at the surface of the membrane. This unique topology and its
associated functional counterpart are metaphorically referred to
as the “snorkeling” effect (Strandberg and Killian, 2003). By the
same token, Trp, and Tyr have an aromatic structure compatible
with the apolar region of the membrane, but contain an −OH
group (Tyr) or an N atom (Trp) capable of forming hydrogen
bonds with polar groups (Lee, 2003). Nonhelical transmembrane
β structures have also been characterized, for instance in bacterial
cytolysins (Harris and Palmer, 2010), but are less represented than
the widespread α-helical domains in resident plasma membrane
proteins. In this review, we will focus on TM domains with an
α-helical structure and their different modes of interaction with
membrane cholesterol.
CHOLESTEROL STRUCTURE, DYNAMICS, AND MEMBRANE
TOPOLOGY
Cholesterol is a polycyclic amphipathic molecule derived from
the sterane backbone (Fantini and Barrantes, 2009). Its polar sec-
tion is restricted to a single hydroxyl (OH) group which can form
two distinct types of hydrogen bond (acceptor and donor) with a
polar group belonging to either a membrane lipid or a protein.
The apolar section of cholesterol has an asymmetric structure
with two distinct faces, referred to as α and β according to the
system numeration of ring compounds proposed by Rose et al.
(1980) (Figures 1A and B). The α face displays a planar surface,
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FIGURE 1 | Structural properties of cholesterol. The asymmetric
distribution of aliphatic groups (methyl, iso-octyl) linked to the planar
sterane backbone of cholesterol defines two distinct sides referred to as α
and β faces, according to the nomenclature of ring compounds proposed by
Rose et al. (1980). This asymmetric structure of cholesterol is illustrated in a
tube model (A), a sphere model (B), and a molecular surface model (C).
Note that the OH group is closer to the “smooth” α face than to the
“rough” β face.
in contrast with the β face which has a significantly rougher sur-
face owing to the presence of several aliphatic groups (two methyl
groups and a terminal isooctyl chain that are linked to the ster-
ane backbone) (Fantini and Barrantes, 2009) (Figure 1C). The
side chains of branched amino acids such as Ile, Val, or Leu can
interpenetrate these aliphatic “spikes” and are thus particularly
suited for an association with the β face of cholesterol through van
der Waals interactions. This is the case for the cholesterol binding
domain of α-synuclein (Fantini et al., 2011). Moreover, aromatic
side chains can stack onto the α face of cholesterol through CH-
π interactions (Nishio et al., 1995). However, this should not be
taken as an absolute rule since the aliphatic side chains of an α-
helical segment could also form a groove with a planar surface
fitting the α face of cholesterol (Di Scala et al., 2013). Conversely,
an aromatic ring oriented normally with respect to the main
axis of an α-helical region could perfectly well accommodate the
rough β face of cholesterol by intercalating the aromatic structure
between the aliphatic spikes of the lipid.
Another key parameter which determines how cholesterol
interacts with a TM domain of a protein is the membrane
phase to which it belongs. It should be kept in mind that
although cholesterol is concentrated in sphingolipid-enriched
membrane microdomains such as lipid “rafts” (Simons and
Ikonen, 1997; Anderson and Jacobson, 2002) it is also present
outside these microdomains, i.e., in the liquid disordered (Ld)
phase of the plasma membrane that contains high amounts of
glycerophospholipids such as phosphatidylcholine (Fantini et al.,
2002). Studies with model membranes indicate that cholesterol
interacts more favorably with sphingomyelin than with phos-
phatidylcholine (Mattjus and Slotte, 1996) (Figure 2), a behavior
which has been attributed to the presence of a saturated acyl
chain in sphingomyelin compared to a cis-unsaturated chain in
phosphatidylcholine (Fantini et al., 2002). The saturated chain in
FIGURE 2 | Lipid-cholesterol interactions. In the plasma membrane,
cholesterol (Chol) can interact with phosphatidylcholine, e.g.,
palmitoyl-oleyl-phosphatidylcholine (POPC) (panel A) or sphingolipids such
as sphingomyelin (panel B). When cholesterol interacts with POPC, its OH
group is not buried in the complex, and both its α and β faces are available
for TM domains of proteins (A). However, when cholesterol interacts with
SM, a hydrogen bond (H bond) is formed between the OH group of
cholesterol and the NH group of the sphingolipid. This H bond orientates
cholesterol with respect to SM so that only its β face remains available for
TM domains. The OH group of cholesterol is masked by the polar head of
sphingomyelin in a typical “umbrella” effect.
sphingomyelin, together with the trans-unsaturated sphingosine
backbone, would allow maximal van der Waals interactions with
cholesterol. Moreover, phosphatidylcholine (Figure 2A) has car-
bonyl groups which could act as hydrogen bond acceptors, but
is devoid of any hydrogen bond donor group such as the amino
group of sphingomyelin (Figure 2B). Therefore, the association
between cholesterol and phosphatidylcholine relies onweakly dis-
criminative van der Waals forces plus limited hydrogen bond
capabilities. When cholesterol is associated with phosphatidyl-
choline, both its α and β faces (Rose et al., 1980) are potentially
available for an interaction with a TM domain (Figure 2A).
Moreover, the −OH group of cholesterol is not buried in the
phosphatidylcholine/cholesterol complex and thus remains acces-
sible for establishing a hydrogen bond with a TM domain. In
contrast, cholesterol forms condensed lipid complexes with sph-
ingolipids (either sphingomyelin or glycosphingolipids) as shown
in Figure 2B (Radhakrishnan et al., 2000). In these molecular
assemblies, the −OH group of cholesterol is available for the
formation of a stabilizing hydrogen bond with the polar head
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group of the sphingolipid. Thus, this −OH group is not ini-
tially available for a hydrogen bond with a TM domain of a
protein. Sphingolipids generally interact with the α face of choles-
terol, leaving the β face available for the TM domain (Fantini
and Barrantes, 2009). Finally, it is interesting to note that in
model membranes, cholesterol can form two distinct types of
dimers that are stabilized through van der Waals interactions:
(1) transbilayer tail-to-tail dimers (Harris et al., 1995; Mukherjee
and Chattopadhyay, 1996; Rukmini et al., 2001) (Figure 3A);
and (2) dimers formed by the association of two cholesterol
molecules interacting with their respective smooth α faces, leav-
ing the opposite β faces available for protein binding (Figure 3B).
In this latter case, the cholesterol dimer can recruit for instance
two G-protein coupled receptors, thereby inducing their func-
tional dimerization (Figure 3C) (Hanson et al., 2008). That such
cholesterol dimers actually exist in natural plasma membranes
has not been formally demonstrated. Although the intracellular
dynamics of cholesterol has been the subject of intense research
efforts during the last decade (Mesmin and Maxfield, 2009), the
transbilayer distribution of cholesterol has remained uncertain
(Ikonen, 2008). Indeed, despite the fact that cholesterol pref-
erentially interacts with sphingolipids in the exofacial leaflet,
fluorescence quenching studies suggested that it is in fact more
abundant in the cytoplasmic leaflet (Mondal et al., 2009). The
molecular basis for such an asymmetric transbilayer distribution
of plasma membrane cholesterol is unknown. However, the lim-
ited accessibility of cholesterol in the exofacial leaflet, due to its
tight interactions with sphingolipids, could lead to an underes-
timation of its content in this leaflet. Nevertheless, whichever
membrane layer has the highest cholesterol content, cholesterol
is present in both leaflets of the plasma membrane, providing
various interaction possibilities with TM domains. In all cases,
unraveling the molecular mechanisms involved in the interaction
of TM domains with cholesterol may require (1) the description
of the cholesterol/α-helix complex at the molecular/atomic level
and (2) consideration of the lipid/protein environment in which
this interaction occurs.With this inmindwe will now describe the
different types of protein structures capable of interacting with
membrane cholesterol.
THE CRAC DOMAIN
There is little doubt that the most popular cholesterol-
binding domain in the scientific literature is the Cholesterol
Recognition/interaction Amino acid Consensus sequence, gen-
erally referred as the CRAC domain (Li and Papadopoulos,
1998). CRAC is a short linear motif which fulfills a very simple
algorithm, that is, in the N-terminus to C-terminus direction:
a branched apolar Leu or Val residue, followed by a segment
containing 1–5 of any residues, then an aromatic residue that
is mandatory Y, then again a segment containing 1–5 of any
residues, and finally a basic Lys or Arg, i.e., in the one letter
amino acid code, (L/V)-X1−5-(Y)-X1−5-(K/R). The looseness
of the CRAC definition for a motif that mediates binding to
a unique lipid that does not display any structural variation is
rather unexpected, raising some skepticism about its predictive
value (Palmer, 2004; Epand, 2006). However, the motif has been
found in various proteins known to bind cholesterol and in
many cases the interaction between cholesterol and CRAC has
FIGURE 3 | Cholesterol-cholesterol interactions. In model membranes,
two cholesterol molecules can form a tail-to-tail (A) or a face-to-face
(B) complex. In the latter case, the self-recognition properties of
cholesterol can induce the dimerization of membrane receptors (C),
as demonstrated for G-protein-coupled receptors with 7-TM
domains.
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been confirmed by physicochemical approaches. Moreover, sin-
gle mutations in the CRAC domain have been found to markedly
decrease or abolish the interaction, as is the case for the central
aromatic residue which is necessarily Tyr and cannot be replaced
by any other aromatic residue (Jamin et al., 2005; Epand, 2006;
Epand et al., 2006).
Molecular modeling studies have shown that the CRAC motif
belonging to TM domains can have a good fit for choles-
terol, as illustrated for the 5th TM domain of the human type
3 somatostatin receptor (Figure 4A). This CRAC domain lies
between amino acid residues 221–231 and has the following
sequence: VICLCYLLIVVK. It can therefore be either interpreted
as LCYLLIVVK or as VICLCYLLIVVK (amino acid residues that
fulfill the CRAC algorithm in bold and underlined). Detailed
analysis of the energy of interaction between cholesterol and
this CRAC domain showed that the complex involves essentially
five residues, four of which belong to the CRAC motif (V-221,
C-225, L-228, and I-229) and the fifth remaining outside (K-
232), for a total energy of interaction of −43 kJ.mol−1 (Baier
et al., 2011). Surprisingly, the central Tyr residue does not inter-
act with cholesterol, although it is mandatory in the definition
of CRAC. Moreover, the energetic pattern of the cholesterol-
binding site, i.e., 221-VICLCYLLIVVKK-232 (residues involved
in cholesterol binding in bold and underlined) does not overlap
with any of the two CRAC motifs defined above (LCYLLIVVK
or VICLCYLLIVVK). Overall this may indicate that although
the CRAC algorithm has some predictive value for identify-
ing cholesterol-binding motifs in the TM domain, cholesterol
can choose a slightly different fit around the CRAC domain to
adjust its shape to the three-dimensional structure of the TM
domain.
FIGURE 4 | The CRAC/cholesterol complex in a membrane
environment. (A) Docking of cholesterol on the CRAC domain of the TM5
domain of human type 3 somatostatin receptor. The CRAC domain
(221-VICLCYLLIVVKK-232) is located in the cytoplasmic leaflet of the
membrane bilayer. Note that the central Y-226 residue of CRAC is not
involved in cholesterol interaction. The total energy of interaction has been
estimated at −43kJ.mol−1 (Baier et al., 2011). (B) Docking of cholesterol on
the CRAC domain close the TM2 domain of human delta-type opioid
receptor. In this case, the CRAC domain (fragment 74-IVRYTKMK-81) lies
outside the membrane. The aromatic side chain of Y-77 plays a critical role
in this interaction (see Figure 5). The polar-apolar interface of the
membrane is indicated by a dotted gray line.
There is another caveat in the predictive value of the CRAC
algorithm for the specific case of TM domains: the CRAC domain
is an oriented motif, with an apolar amino acid residue at the N-
ter ending and a highly polar, positively charged basic residue at
the C-ter ending. This means that if a CRAC motif belongs to
a TM domain and allows this domain to interact with choles-
terol, several parameters other than the classical CRAC algorithm
have to be fulfilled. First, the basic residue at the C-term end-
ing should be located at the lipid-water interface to ensure an
optimal interaction with the membrane structure. Therefore, if
the TM domain containing the CRAC motif crosses the mem-
brane in the N-term to C-term direction (i.e., with the N-term
region extracellular and the C-term region cytoplasmic), then
it will interact with cholesterol in the cytoplasmic leaflet of the
plasma membrane (Figure 4A). Conversely, if the TM domain
crosses the plasma membrane in the opposite direction (i.e., the
N-term region cytoplasmic and the C-term region extracellular),
then it will interact with cholesterol in the extracellular leaflet.
In both cases, the amino acid residues of the variable segments
separating L/V from Y and Y from K/R can still vary, but they
must be apolar because they are embedded in the apolar part of
the membrane. Since the original definition of the CRAC domain
did not specifically take the membrane insertion of the motif into
consideration, the X amino acid residues could be any residue.
For CRAC motifs belonging to TM domains, the definition
should therefore be restricted to (L/V)-X1−5-(Y)-X1−5-(K/R)
with apolar X residues compatible with the hydrophobic mem-
brane environment, otherwise the CRAC algorithm could incor-
rectly predict the presence of a potential cholesterol-binding
domain that in fact lies outside the membrane. This particu-
lar case is illustrated for the human delta-type opioid receptor,
which contains a CRAC motif the juxtamembrane domain just
upstream of the 2nd TM domain (Figure 4B). The sequence of
this CRAC domain is 74-IVRYTKMK-81, whereas the 2nd TM
domain encompasses residues 85–102. As a matter of fact, the
very high polarity of this CRAC motif restricts its location out-
side the membrane. Nevertheless, as a bona fide CRAC domain,
the IVRYTKMK sequence has a high affinity for cholesterol, with
a total energy of interaction of −49 kJ.mol−1, as calculated from
docking studies (Baier et al., 2011). The amino acid residues
involved in cholesterol binding are I-74, V-75, R-76, Y-77, and
T-78, which can be summarized as a contiguous IVRYTKMK
motif containing two of the three residues that define the CRAC
domain, including the central and mandatory Tyr residue. This
aromatic residue (Y-77) contributes −26 kJ.mol−1, which rep-
resents about 50% of the total energy of interaction of the
CRAC/cholesterol complex. Indeed, the side chain of Y-77 binds
to cholesterol through a CH-π stacking interaction with the B
ring of sterane, whereas its OH group can contribute to a net-
work of electrostatic interactions that also includes the polar
OH group of cholesterol (Figure 5). Nevertheless, the predicted
membrane topology of the human delta-type opioid receptor
suggests that this CRAC domain lies outside the membrane so
that its interaction with cholesterol, although theoretically pos-
sible, is unlikely (Figure 4B). Despite these caveats there are
numerous cases of CRAC motifs within TM domains, illustrat-
ing the overall robustness of the CRAC algorithm for predicting
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FIGURE 5 | Molecular mechanisms of cholesterol-CRAC interaction.
This figure shows a detailed analysis of the interaction between
cholesterol and the CRAC domain of the human delta-type opioid
receptor (see Figure 4). Three distinct views of the complex are shown,
with residues I-74, Y-77, and K-81 enlightened. The NH+3 of K-81, and the
OH groups of Y-77 and cholesterol are rejected in a polar area where
they can form a network of energetically favored electrostatic interactions
(including hydrogen bonds). The aromatic side chain of Y-77 stacks onto
the B ring of sterane backbone through typical CH-π stacking
interactions. The isooctyl chain of cholesterol interacts with the aliphatic
side chains of I-74 (not shown) and V-75. The sterane rings are indicated
for cholesterol in the right panel.
cholesterol-binding sites in TM segments of integral membrane
proteins (Epand, 2006; Epand et al., 2010; Gimpl, 2010; Paila
and Chattopadhyay, 2010), including G-protein coupled recep-
tors of several distinct neurotransmitters (Jafurulla et al., 2011;
Oddi et al., 2011; Sengupta and Chattopadhyay, 2012). However,
in some instances, bioinformatics analysis of the amino acid
sequence of some membrane proteins failed to identify any CRAC
motifs encased within TM domains. This is the case for the
human nicotinic acetylcholine receptor (AChR) and this par-
ticular situation led to the development of a new algorithm
for predicting cholesterol-binding domains in TM segments of
membrane proteins.
THE CARC DOMAIN
The new cholesterol-binding domain is similar to the CRAC
sequence, but exhibits the opposite orientation along the
polypeptide chain (i.e., constitutes an “inverted CRAC” domain),
i.e., (K/R)-X1−5-(Y/F)-X1−5-(L/V) from the N-term ending to
the C-term ending (Baier et al., 2011), for which reason the
sequence was coined “CARC.” Besides the reverse orientation,
CARC is distinct from CRAC in that the central aromatic amino
acid can be either Tyr or Phe. Basically, the CARC motif is
based on a sequence of amino acids which includes, from N-
terminus to C-terminus endings, a basic (Lys or Arg), an aro-
matic (Tyr or Phe) and a branched aliphatic residue (Leu or
Val). The presence of the basic residue ensures that the CARC
motif is correctly positioned at the polar-apolar interface of a
TM domain, exactly where cholesterol is supposed to be. This is
due to the “snorkeling” effect discussed above (Strandberg and
Killian, 2003) which can be attributed to the fact that the long
and flexible side chain of lysine (or arginine) is buried in the
hydrophobic part of the membrane, whereas the cationic group
emerges at the membrane surface (Segrest et al., 1990; Baier et al.,
2011). Interestingly, Arg and Lys residues are more frequently
found in the N-terminal than in the C-terminal section of a
TM domain, indicating that snorkeling is an asymmetric phe-
nomenon (Strandberg and Killian, 2003). The specific topology
of the CARC sequence (K/R. . . Y/F. . . L/V, from the N-terminus
to the C-terminus) implies that the key residues following K/R in
the motif (i.e., Y/F and L/V) actually belong to a TM domain, and
this is consistent with the fact that both aromatic and aliphatic
residues have an apolar side chain.
Moreover, even if there is no direct interaction between choles-
terol and K/R, the basic amino acid in the first position is
critical for identifying a functional CARC motif belonging to
a TM domain. Incidentally, this also explains why the previ-
ously characterized CRAC motif, which has an inverse topology
(L/V. . . Y. . . K/R, from the N-terminus to the C-terminus), does
not always belong to a TM domain (Figure 4B). Furthermore,
the tyrosine residue (an absolute requirement for CRAC) can be
functionally replaced by Phe in the CARC motif. In the CRAC
motif, the phenol group of tyrosine is often required to form a
H-bond with the OH group of cholesterol (Epand et al., 2010),
and this would not be possible with Phe. In the case of CARC,
the interaction between the aromatic amino acid and choles-
terol occurs in the apolar region of the membrane, far from the
OH group of cholesterol, and the interaction with cholesterol
is mediated almost exclusively by the CH-π stacking arrange-
ment between the aromatic ring of the amino acid (either Tyr
or Phe) and one of the sterane rings of cholesterol (Figure 6).
Finally, the requirement for Leu or Val is justified by the need
to accommodate the crevices and asperities of the cholesterol
molecule (Fantini and Barrantes, 2009) through numerous van
der Waals contacts between these residues and cholesterol. The
human type 3 somatostatin receptor illustrates these biochemi-
cal principles: in this case, the CARC domain corresponds to the
203-RAGFIIYTAAL-213, which overlaps the extracellular leaflet
of the 5th domain of the receptor (this TM domain encom-
passes the segment 206–231). Thus, though as discussed above the
Arg residue does not belong to the TM domain, it is important
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FIGURE 6 | The CARC/cholesterol complex. This figure shows the
docking of cholesterol on the CARC domains of the TM5 domain of the
human type 3 somatostatin receptor. The CARC domain (fragment
203-RAGFIIYTAAL-213) is located in the extracellular leaflet of the TM5
domain of the receptor. Two distinct views of the complex are shown, one
with the whole TM5 domain (left panel), the other with residues R-203 and
F-206 enlightened. Note the CH-π stacking interaction of the phenyl ring of
F-206 onto the A ring of the sterane backbone of cholesterol. The large
aliphatic chain of L-213 interacts with the isooctyl group of cholesterol.
for defining the correct orientation of the TM domain with
the CARC motif in the exofacial leaflet of the plasma mem-
brane. All the key amino acid residues that define the CARC
motif (R-203, F-206, Y-209, and L-213) do interact with choles-
terol, rendering a total energy of interaction of −54 kJ.mol−1
(Figure 6). What is particularly interesting in this CARC motif
is that it contains not just one but two aromatic residues that
both stack onto cholesterol through near-perfect CH-π inter-
actions. Correspondingly, the energetic contribution of these
aromatic residues for cholesterol binding is high: −18.2 kJ.mol−1
and −14.7 kJ.mol−1 for F-206 and Y-209, respectively. The inter-
action of L-213 with the isooctyl chain of cholesterol accounts for
−10.0 kJ.mol−1. This illustrates the efficiency of van der Waals
interactions between the branched side chain residues and the
rough β face of cholesterol. Overall, these unique biochemical
features explain why the CARC domains detected in the AChR
and its homologous ion channels cover a wide evolutionary span
from bacteria to humans (Baier et al., 2011). The CARC motif
is also present in the TM domains of the important group of
G-protein coupled receptors, which, together with the AChR
and other neurotransmitter receptors, are thought to play a role
in the pathogenesis of Alzheimer’s disease, in connection with
high cholesterol content (Barrantes et al., 2010; Thathiah and De
Strooper, 2011).
Finally, it is worth noting that the same TM domain can
contain both a CRAC and a CARC sequence, allowing the
simultaneous binding of two cholesterol molecules, one in each
membrane leaflet, in a tail-to-tail configuration. This case is illus-
trated in the 5th TM domain of the human type 3 somatostatin
receptor (CRAC in the cytoplasmic leaflet, and CARC in the
exofacial leaflet) (Figure 7).
FIGURE 7 | Occurrence of two cholesterol binding motifs (CRAC and
CARC) in the same TM domain. An example of the simultaneous
occurrence of two cholesterol-recognition motifs in the same TM segment
is given by the 5th TM domain of the human type 3 somatostatin
receptor, which possesses a CRAC domain in the cytoplasmic leaflet (in
blue) and a CARC domain in its exofacial leaflet (in yellow). The calculated
energy of interaction of each domain with cholesterol is indicated. The
surface rendering of the TM domain is particularly suited to visualize the
three-dimensional interaction with cholesterol (rendered as space fill
models).
TILTED PEPTIDES
There are several instances in which a cholesterol-binding site is
functionally characterized in a TM segment without the help of
the CRAC or CARC algorithms. This has recently been shown
to be the case for α-synuclein, the neural protein associated
with Parkinson disease, which can form oligomeric ion chan-
nels in the plasma membrane of neurons (Fantini and Yahi,
2010, 2011). This protein contains a CRAC domain which has
been shown to bind cholesterol with low affinity. However, the
domain is located outside the membrane-spanning regions of
the proteins that supposedly interact with cholesterol and dis-
play neither CRAC nor CARC motifs (Fantini et al., 2011).
Nevertheless, a second cholesterol-binding domain has been suc-
cessfully characterized in α-synuclein, corresponding to a tilted
peptide known to be toxic for cultured neurons, namely the seg-
ment 67-GGAVVTGVTAVA-78 (Fantini et al., 2011). What is
intriguing about this peptide is that it does not contain the basic
and aromatic residues that are mandatory in both the CRAC
and CARC algorithms. Indeed, the definition of tilted peptides
is functional, not sequence-based. Tilted peptides are short heli-
cal protein fragments that are able to disturb the organization
of the molecular system into which they insert. They are char-
acterized by an asymmetric distribution of their hydrophobic
residues, which induces a tilted orientation (around 45◦) toward
the membrane plane (Lins et al., 2008). Because they induce a
significant distortion of the membrane structure, tilted peptides
are involved in the fusion process triggered by viral glycoproteins
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(Charloteaux et al., 2009). This is the case with the tilted pep-
tide of α-synuclein, which binds cholesterol with a tilt angle of
46◦ (Crowet et al., 2007). Despite the lack of aromatic residues,
the contribution of apolar aliphatic residues accounts for a total
energy of interaction of−53 kJ.mol−1, which is comparable to the
values obtained for both CRAC and CARC domains. This fur-
ther illustrates how efficient van der Waals interactions between
branched apolar residues and the β face of cholesterol can be.
Similarly, a linear motif (22-EDVGSNKGAIIGLM-35) including
a part of the tilted domain of Alzheimer’s β-amyloid peptide has
been identified as a high affinity binding site for cholesterol (Di
Scala et al., 2013).
An example of the interaction between a fusogenic tilted pep-
tide and cholesterol is shown in Figure 8. This is the tilted peptide
of the transmembrane glycoprotein gp41 of HIV-1. The tilted ori-
entation of the peptide with respect to cholesterol is clearly visible
in the model, and the tilt angle of 41◦ is close to the experimen-
tal value (Charloteaux et al., 2006). The association of the tilted
peptide with cholesterol is mediated by a series of van der Waals
interactions for a total energy of interaction of −48.5 kJ.mol−1.
Tilted peptides have been detected in various proteins otherwise
known to require cholesterol for their membrane insertion pro-
cess, including amyloidogenic and viral fusion proteins (Fantini
et al., 2011). This suggests that tilted peptides have evolved in
such a way as to acquire the cholesterol-binding properties that
facilitate their biological functions.
OTHER CHOLESTEROL-BINDING MOTIFS
An important issue to resolve is whether cholesterol can inter-
act with TM domains of protein lacking a CRAC, a CARC or a
tilted domain. If we consider any possible interaction between a
membrane protein and its surrounding lipids, including choles-
terol, then the answer might be yes. In this respect, two distinct
types of lipid-protein interactions in the membrane environ-
ment should be considered. Lipids in the first boundary shell,
or annulus, are referred to as annular or belt lipids (see review
FIGURE 8 | How cholesterol interacts with a tilted peptide. Docking of
cholesterol with the N-terminal part of HIV-1 gp41, i.e., the fusion peptide.
The apolar part of cholesterol interacts with the aromatic ring of F-8 through
CH-π (but not stacking) interactions. The OH group of cholesterol is close to
the α-NH3+ group of the peptide (N-terminus ending). The angle between
the helix axis of the tilted fragment of the fusogenic tilted peptide of gp41
is 41◦. The calculated energy of interaction is −48.5 kJ.mol−1.
in Marsh and Pali, 2012). Such annular lipids interact with the
membrane-embedded surface of the protein (Lee, 2011). In addi-
tion, there is a second category of lipids that are buried to a
greater or lesser extent in the protein. Such lipids are found bound
between TM domains and are referred to as non-annular lipids
(Lee, 2011; Marsh and Pali, 2012). Because they are bound to the
protein surface, annular lipids can be exchanged for other mem-
brane lipids. This is usually not the case for non-annular lipids
that are less or not accessible at all to surrounding membrane
lipids. Indeed, non-annular binding sites may involve several TM
domains that form a 3D binding site for the lipid. For instance,
several potential cholesterol-binding residues located in distinct
TM domains of the 5-HT1A serotonin receptor were identi-
fied by comparison with the conserved cholesterol-consensus
motifs in the β2-adrenergic receptor—as predicted from its crys-
tal structure (Paila et al., 2009). Interestingly, the evolutionary
conserved residues of this non-annular binding site are typically
those found in CRAC and CARC domains, i.e., a combination
of aromatic (Y-73 in TM2, W-161 in TM4), basic (R-151 in
TM4) and aliphatic (I-157 in TM4) residues. Thus, the molec-
ular mechanisms of cholesterol binding described for the CRAC
and the CARC domains should probably also apply for this 3D
binding site.
Overall, the interaction between membrane proteins (or pep-
tides) and annular/non-annular lipids has been studied by three
main approaches: 2H nuclear magnetic resonance (NMR), spin-
label electron paramagnetic resonance (ESR) and X-ray crystal-
lography (see reviews in Marsh, 2008, 2010). This has enabled
determination of the stoichiometry of the lipid–protein inter-
action, the selectivity of the protein for different lipids and the
amino acid residues physically involved in lipid binding. X-ray
crystallography is of particular value since it can give a precise
description of lipid-protein contacts at the atomic scale.
Unfortunately, very few 3D structures of protein-cholesterol
complexes are available in the literature. In 2008, Hanson et al.
published the 2.8Å resolution crystal structure of a thermally-
stabilized human β2-adrenergic receptor bound to cholesterol.
The cholesterol binding site of this receptor was defined as a 3D
motif involving the 1st, 2nd, 3rd, and 4th TM domains (referred
to as TM1, TM2, TM3, and TM4). Among these domains, TM2
and TM4 appeared particularly critical for cholesterol bind-
ing. Interestingly, TM4 contains an aromatic tryptophan residue
(W-158) that is highly conserved among human G-protein cou-
pled receptors. The aromatic side chain of W-158 stacks onto
cholesterol through a CH-Pi interaction with ring D of the sterol.
The binding site also involves two other amino acid residues of
TM4 (R-151 and L-163) and a second aromatic residue located in
TM2 (Tyr-70).
As noted by Hanson et al. (2008), the amino acid sequence
of TM4 contains the combination of basic (R), aromatic
(W) and aliphatic (L/V) residues found in CRAC domains
(151-RVIILMVWIVSGLTSFLPIQMHWY-174). However, this
sequence does not fulfill the criteria of the CRAC domain.
Moreover, it is even closer to a CARC domain (with the typ-
ical R—W—L motif), except that there are 6 residues between
R-151 and W-158, which exceeds by one unit the maximal num-
ber of 5 residues allowed by the CARC algorithm. Finally, the
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unique spatial distribution of amino acid residues that are impor-
tant for cholesterol interaction was used to define a consensus
3D binding motif among human G-protein-coupled recep-
tors as follows: [4.39–4.43(R,K)]—[4.50(W,Y)]—[4.46(I,V,L)]—
[2.41(F,Y)], according to the Ballesteros–Weinstein numbering
scheme (Ballesteros and Weinstein, 1995).
Besides the human β2-adrenergic receptor, very few mem-
brane proteins have been co-crystallized with cholesterol.
NMR studies have been recently performed on mixed choles-
terol/phosphatidylcholine micelles containing C99, a prote-
olytic fragment of Alzheimer’s amyloid precursor protein (APP)
(Barrett et al., 2012). Although this protein does not contain a
CRAC or a CARC domain, its unique TM domain displays a
cholesterol binding site consisting of a series of scattered Gly
residues (GXXXG motifs) that confer an unusual high flexibil-
ity on the TM domain. These glycine residues are involved in
cholesterol binding, which is chiefly mediated by van der Waals
interactions between the apolar moiety of cholesterol and apolar
residues within the motif (i.e., the aliphatic Ala, Ile, Val, and the
aromatic Phe).
CONCLUSIONS AND PERSPECTIVES
At first glance, this review of cholesterol-binding sites encased in
TM domains of proteins may appear rather complex. Two con-
sensus domains, CRAC and CARC, have been characterized. As
a cholesterol-binding domain present in a TM domain, CARC
appears more consistent than CRAC in predicting cholesterol-
recognition motifs in integral membrane proteins, especially for
predicting cholesterol-binding sites located in the exofacial leaflet
of the plasma membrane. The CRAC algorithm is generally rele-
vant (Sengupta and Chattopadhyay, 2012), but it can occasionally
mis-predict unrealistic cholesterol-binding domains outside TM
domains (Figure 4B). Fusogenic tilted peptides lacking a CARC
or a CRAC domain can interact with cholesterol, although they
do not contain the basic and aromatic amino acid residues that
are mandatory for both the CARC and CRAC algorithms. Finally
non-annular cholesterol-binding sites can be formed by the coop-
eration of several TM domains of G-protein coupled receptors,
rendering the prediction of such binding domains particularly
difficult.
Linear and 3D binding sites for cholesterol might have distinct
biological functions. In bringing together several TM domains,
cholesterol could exert a condensing effect on the whole protein,
which, e.g., in the case of the 5-HT1 A receptor could help the
protein to acquire some of its functional characteristics, including
the delineation of the ligand-binding pocket (Paila et al., 2011). In
contrast, cholesterol interacting with only one TM domain at the
periphery of a receptor protein would be more suited to bring-
ing together two distinct receptor macromolecules and triggering
their dimerization, a key step in signal transduction cascades
(Figure 3C).
This may explain why various types of cholesterol-binding
motifs can be found in TM domains. These motifs may vary
greatly in length, amino acid sequence, and can either be lin-
ear such as the CRAC (Li and Papadopoulos, 1998), CARC
(Baier et al., 2011), and tilted peptides (Fantini et al., 2011) or
three-dimensional, e.g., cholesterol consensus motifs (Hanson
et al., 2008) and sterol sensing domains (Garmy et al., 2005).
Nevertheless, common molecular mechanisms seem to con-
trol the interaction of transmembrane proteins with choles-
terol. These mechanisms include the delineation of a polar
area to accommodate the OH group of cholesterol at the
membrane-water interface, and the establishment of numerous
van der Waals interactions in the apolar zone of the mem-
brane (Epand et al., 2006; Baier et al., 2011). These van der
Waals interactions comprise London forces and CH-π interac-
tions. London forces require an optimal geometric fit between
cholesterol and the apolar side chains of the amino acid residues
that belong to the motif. This explains why branched amino
acid residues such as Ile, Val, and Leu are overrepresented
in cholesterol-binding sites. Aromatic residues can stack onto
the smooth α face of cholesterol or intercalate between the
aliphatic spikes emerging from the rough β face of cholesterol.
These simple biochemical rules probably apply to most if not
all cholesterol-binding sites that are part of TM domains of
proteins.
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